DYNACIRC CR Drug Patent Profile
✉ Email this page to a colleague
When do Dynacirc Cr patents expire, and what generic alternatives are available?
Dynacirc Cr is a drug marketed by Glaxosmithkline Llc and is included in one NDA.
The generic ingredient in DYNACIRC CR is isradipine. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the isradipine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dynacirc Cr
A generic version of DYNACIRC CR was approved as isradipine by WATSON LABS TEVA on January 5th, 2006.
Summary for DYNACIRC CR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 119 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,369 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | DYNACIRC CR at DailyMed |
Recent Clinical Trials for DYNACIRC CR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Texas at Austin | Early Phase 1 |
| National Institute on Drug Abuse (NIDA) | Early Phase 1 |
| The Parkinson Study Group | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for DYNACIRC CR
US Patents and Regulatory Information for DYNACIRC CR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-001 | Jun 1, 1994 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-002 | Jun 1, 1994 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DYNACIRC CR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-002 | Jun 1, 1994 | ⤷ Try a Trial | ⤷ Try a Trial |
| Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-002 | Jun 1, 1994 | ⤷ Try a Trial | ⤷ Try a Trial |
| Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-001 | Jun 1, 1994 | ⤷ Try a Trial | ⤷ Try a Trial |
| Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-001 | Jun 1, 1994 | ⤷ Try a Trial | ⤷ Try a Trial |
| Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-001 | Jun 1, 1994 | ⤷ Try a Trial | ⤷ Try a Trial |
| Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-002 | Jun 1, 1994 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DYNACIRC CR
See the table below for patents covering DYNACIRC CR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| United Kingdom | 2041358 | BENZOXADIAZOLES AND BENZOTHIADIAZOLES | ⤷ Try a Trial |
| South Africa | 8807362 | ⤷ Try a Trial | |
| Germany | 2860708 | ⤷ Try a Trial | |
| Switzerland | 643841 | Novel 1,4-dihydropyridine derivatives, their preparation and use | ⤷ Try a Trial |
| Ireland | 882960 | ⤷ Try a Trial | |
| New Zealand | 187617 | 1,4-DIHYDROPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
